XL413

TargetMol
Product Code: TAR-T3352
Supplier: TargetMol
CodeSizePrice
TAR-T3352-1mg1mg£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3352-5mg5mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3352-10mg10mg£237.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3352-25mg25mg£402.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3352-50mg50mg£564.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3352-100mg100mg£774.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. XL-413 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells.
CAS:
1169558-38-6
Formula:
C14H12ClN3O2
Molecular Weight:
289.72
Pathway:
Stem Cells; Chromatin/Epigenetic; Metabolism; JAK/STAT signaling; Cell Cycle/Checkpoint; GPCR/G Protein
Purity:
0.98
SMILES:
Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1
Target:
cholecystokinin; Casein Kinase; Pim; CDK

References

Koltun ES, et al. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31. Yu Z, Deng P, Chen Y, et al. Inhibition of the PLK1?Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer. Advanced Science. 2021: 2100759.